Acknowledgements
This trial was financed via an academic partnership between the Louis-H Lafontaine Foundation and AstraZeneca Pharmaceuticals and via a grant from the Fonds de la Recherche en Santé du Québec (FRSQ). E.S. is holder of the Eli Lilly Canada Chair of Schizophrenia from the University of Montreal. S.P. is holder of a research scholarship from the FRSQ.